Naratriptan
Identification
- Summary
Naratriptan is a 5-HT1B/1D receptor agonist used to treat migraines.
- Generic Name
- Naratriptan
- DrugBank Accession Number
- DB00952
- Background
Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
- Weight
- Average: 335.464
Monoisotopic: 335.166747749 - Chemical Formula
- C17H25N3O2S
- Synonyms
- N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide
- N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
- Naratriptán
- Naratriptan
- Naratriptanum
Pharmacology
- Indication
For the acute treatment of migraine attacks with or without aura in adults.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Acute migraine with aura •••••••••••• ••••• Treatment of Acute migraine without aura •••••••••••• ••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Naratriptan is a selective agonist of serotonin (5-hydroxytryptamine; 5-HT) type 1B and 1D receptors. It is structurally and pharmacologically related to other selective 5-HT1B/1D receptor agonist. Naratriptan has only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Naratriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Naratriptan in humans.
- Mechanism of action
Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.
Target Actions Organism A5-hydroxytryptamine receptor 1A agonistHumans A5-hydroxytryptamine receptor 1D agonistHumans A5-hydroxytryptamine receptor 1B agonistHumans A5-hydroxytryptamine receptor 1F agonistHumans - Absorption
Well absorbed (74% oral biovaility), absorption is rapid with peak plasma concentrations after 2-5 hours. The rate of absorption is slower during a migraine attack.
- Volume of distribution
- 170 L
- Protein binding
28%-31% (over the concentration range of 50 to 1000 ng/mL)
- Metabolism
Primarily hepatic. In vitro, naratriptan is metabolized by a wide range of cytochrome P450 isoenzymes into a number of inactive metabolites.
- Route of elimination
Not Available
- Half-life
5-8 hours
- Clearance
- 6.6 mL/min/kg
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Symptoms of overdose include light-headedness, loss of coordination, tension in the neck, and tiredness.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 --- (T;T) / (C;T) T Allele Effect Directly Studied Patients with this genotype have an increased likelihood of responding to naratriptan when treating (condition: cluster headache). Details
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when Naratriptan is combined with 1,2-Benzodiazepine. Acebutolol Naratriptan may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of hypertension can be increased when Naratriptan is combined with Aceclofenac. Acemetacin The risk or severity of hypertension can be increased when Naratriptan is combined with Acemetacin. Acenocoumarol The risk or severity of adverse effects can be increased when Naratriptan is combined with Acenocoumarol. - Food Interactions
- Take with or without food. The absorption is unaffected by food.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Naratriptan hydrochloride 10X8X4P12Z 143388-64-1 AWEZYKMQFAUBTD-UHFFFAOYSA-N - Product Images
- International/Other Brands
- Naramig
- Brand Name Prescription Products
- Generic Prescription Products
Categories
- ATC Codes
- N02CC02 — Naratriptan
- Drug Categories
- Agents that produce hypertension
- Amines
- Analgesics
- Antidepressive Agents
- Antimigraine Preparations
- Biogenic Amines
- Biogenic Monoamines
- Cardiovascular Agents
- Central Nervous System Depressants
- Heterocyclic Compounds, Fused-Ring
- Indoles
- Monoamine Oxidase A Substrates
- Nervous System
- Neurotransmitter Agents
- Selective Serotonin 5-HT1 Receptor Agonists
- Selective Serotonin Agonists
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Serotonin 1b Receptor Agonists
- Serotonin 1d Receptor Agonists
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Agents
- Serotonin Modulators
- Serotonin Receptor Agonists
- Serotonin-1b and Serotonin-1d Receptor Agonist
- Triptans
- Vasoconstrictor Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 3-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 3-position.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Indoles and derivatives
- Sub Class
- Indoles
- Direct Parent
- 3-alkylindoles
- Alternative Parents
- Aralkylamines / Substituted pyrroles / Piperidines / Organosulfonamides / Organic sulfonamides / Benzenoids / Heteroaromatic compounds / Aminosulfonyl compounds / Trialkylamines / Azacyclic compounds show 3 more
- Substituents
- 3-alkylindole / Amine / Aminosulfonyl compound / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Heteroaromatic compound / Hydrocarbon derivative / Organic nitrogen compound show 15 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- sulfonamide, tryptamines, heteroarylpiperidine (CHEBI:7478)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- QX3KXL1ZA2
- CAS number
- 121679-13-8
- InChI Key
- AMKVXSZCKVJAGH-UHFFFAOYSA-N
- InChI
- InChI=1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3
- IUPAC Name
- N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethane-1-sulfonamide
- SMILES
- CNS(=O)(=O)CCC1=CC2=C(NC=C2C2CCN(C)CC2)C=C1
References
- Synthesis Reference
Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan, Sandip Vasant Chikhalikar, Maruti Ghagare, "Process for the synthesis of naratriptan." U.S. Patent US20120220778, issued August 30, 2012.
US20120220778- General References
- Massiou H: Naratriptan. Curr Med Res Opin. 2001;17 Suppl 1:s51-3. [Article]
- Lambert GA: Preclinical neuropharmacology of naratriptan. CNS Drug Rev. 2005 Autumn;11(3):289-316. [Article]
- Villalon CM, Centurion D, Valdivia LF, de Vries P, Saxena PR: Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol. 2003 Mar;1(1):71-84. [Article]
- External Links
- Human Metabolome Database
- HMDB0015087
- KEGG Drug
- D08255
- KEGG Compound
- C07792
- PubChem Compound
- 4440
- PubChem Substance
- 46507243
- ChemSpider
- 4287
- BindingDB
- 50073682
- 141366
- ChEBI
- 7478
- ChEMBL
- CHEMBL1278
- ZINC
- ZINC000000004076
- Therapeutic Targets Database
- DAP000890
- PharmGKB
- PA450597
- Guide to Pharmacology
- GtP Drug Page
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Naratriptan
- FDA label
- Download (1.93 MB)
- MSDS
- Download (29.8 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Other Workplace Migraine Treatment 1 4 Terminated Not Available Antisocial Personality Disorder (ASPD) / Impulse Regulation Disorder / Intermittent Explosive Disorder / Psychosis 1 4 Terminated Treatment Post-Traumatic Headaches 1 3 Withdrawn Treatment Headache / Migraine 2 1, 2 Unknown Status Treatment Migraine 1
Pharmacoeconomics
- Manufacturers
- Glaxosmithkline
- Paddock laboratories inc
- Roxane laboratories inc
- Sandoz inc
- Teva pharmaceuticals usa
- Packagers
- GlaxoSmithKline Inc.
- Paddock Labs
- Roxane Labs
- Sandoz
- Teva Pharmaceutical Industries Ltd.
- Dosage Forms
Form Route Strength Tablet Oral 1 mg Tablet, coated Oral 2.5 mg Tablet, coated Oral 250000 mg Tablet Oral 1 mg/1 Tablet Oral 2.5 mg/1 Tablet, coated Oral 1 mg/1 Tablet, coated Oral 2.5 mg/1 Tablet, film coated Oral 1 mg/1 Tablet, film coated Oral 2.5 mg/1 Tablet, film coated Oral 2.50 mg Tablet Oral 2.5 mg Tablet, film coated Oral 2.5 mg - Prices
Unit description Cost Unit Amerge 9 2.5 mg tablet Box 277.47USD box Amerge 9 1 mg tablet Box 275.67USD box Amerge 1 mg tablet 32.77USD tablet Amerge 2.5 mg tablet 32.77USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US4997841 No 1991-03-05 2010-07-07 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 246 °C (HCl salt) Not Available water solubility 35 mg/mL Not Available logP 1.6 Not Available - Predicted Properties
Property Value Source Water Solubility 0.114 mg/mL ALOGPS logP 2.16 ALOGPS logP 1.44 Chemaxon logS -3.5 ALOGPS pKa (Strongest Acidic) 11.55 Chemaxon pKa (Strongest Basic) 9.18 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 65.2 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 94.26 m3·mol-1 Chemaxon Polarizability 38 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9668 Caco-2 permeable - 0.7657 P-glycoprotein substrate Substrate 0.6958 P-glycoprotein inhibitor I Non-inhibitor 0.6055 P-glycoprotein inhibitor II Non-inhibitor 0.8139 Renal organic cation transporter Non-inhibitor 0.5982 CYP450 2C9 substrate Non-substrate 0.8257 CYP450 2D6 substrate Non-substrate 0.5565 CYP450 3A4 substrate Substrate 0.6693 CYP450 1A2 substrate Inhibitor 0.5521 CYP450 2C9 inhibitor Non-inhibitor 0.9034 CYP450 2D6 inhibitor Non-inhibitor 0.6785 CYP450 2C19 inhibitor Non-inhibitor 0.804 CYP450 3A4 inhibitor Non-inhibitor 0.5914 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.707 Ames test Non AMES toxic 0.6042 Carcinogenicity Non-carcinogens 0.8226 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.5630 LD50, mol/kg Not applicable hERG inhibition (predictor I) Strong inhibitor 0.608 hERG inhibition (predictor II) Inhibitor 0.6772
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0563-6592000000-ddbcdc8fb1564ab67954 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-0009000000-84e34a57fe2a3792a8dc Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-0009000000-938c8fd42cb3bc2d09cf Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-1093000000-e15a2a09f5dc85ea8c7b Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-052r-0097000000-fb5fa1c85cc931972785 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-01t9-2091000000-a3b656e9b053c5c77dc6 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-052u-2892000000-dff9f56a028a0118dd70 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 198.1950207 predictedDarkChem Lite v0.1.0 [M-H]- 170.33667 predictedDeepCCS 1.0 (2019) [M+H]+ 198.9714207 predictedDarkChem Lite v0.1.0 [M+H]+ 172.69467 predictedDeepCCS 1.0 (2019) [M+Na]+ 198.2612207 predictedDarkChem Lite v0.1.0 [M+Na]+ 178.85826 predictedDeepCCS 1.0 (2019)
Targets
![](https://go.drugbank.com/assets/locked/DrugTargets2-682eb846d210ae4bf33ca03febccfb57bb1c61318e699b729e5df4dfab2c5b67.png)
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
- Gene Name
- HTR1A
- Uniprot ID
- P08908
- Uniprot Name
- 5-hydroxytryptamine receptor 1A
- Molecular Weight
- 46106.335 Da
References
- Boers PM, Donaldson C, Zagami AS, Lambert GA: Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B/1D) receptors in the cat: implications for migraine therapy. Cephalalgia. 2004 Feb;24(2):99-109. [Article]
- Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
- Gene Name
- HTR1D
- Uniprot ID
- P28221
- Uniprot Name
- 5-hydroxytryptamine receptor 1D
- Molecular Weight
- 41906.38 Da
References
- Hargreaves RJ, Shepheard SL: Pathophysiology of migraine--new insights. Can J Neurol Sci. 1999 Nov;26 Suppl 3:S12-9. [Article]
- Donaldson C, Boers PM, Hoskin KL, Zagami AS, Lambert GA: The role of 5-HT1B and 5-HT1D receptors in the selective inhibitory effect of naratriptan on trigeminovascular neurons. Neuropharmacology. 2002 Mar;42(3):374-85. [Article]
- Pauwels PJ, Colpaert FC: Selective antagonism of human 5-HT1D and 5-HT1B receptor-mediated responses in stably transfected C6-glial cells by ketanserin and GR 127,935. Eur J Pharmacol. 1996 Apr 4;300(1-2):141-5. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Akin D, Onaran HO, Gurdal H: Agonist-directed trafficking explaining the difference between response pattern of naratriptan and sumatriptan in rabbit common carotid artery. Br J Pharmacol. 2002 May;136(2):171-6. [Article]
- Hoskin KL, Lambert GA, Donaldson C, Zagami AS: The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res. 2004 Feb 13;998(1):91-9. [Article]
- Boers PM, Donaldson C, Zagami AS, Lambert GA: Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B/1D) receptors in the cat: implications for migraine therapy. Cephalalgia. 2004 Feb;24(2):99-109. [Article]
- Johnston MM, Rapoport AM: Triptans for the management of migraine. Drugs. 2010 Aug 20;70(12):1505-18. doi: 10.2165/11537990-000000000-00000. [Article]
- Dulli DA: Naratriptan: an alternative for migraine. Ann Pharmacother. 1999 Jun;33(6):704-11. [Article]
- Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. [Article]
- Massiou H: Naratriptan. Curr Med Res Opin. 2001;17 Suppl 1:s51-3. [Article]
- Lambert GA: Preclinical neuropharmacology of naratriptan. CNS Drug Rev. 2005 Autumn;11(3):289-316. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
- Gene Name
- HTR1B
- Uniprot ID
- P28222
- Uniprot Name
- 5-hydroxytryptamine receptor 1B
- Molecular Weight
- 43567.535 Da
References
- Akin D, Onaran HO, Gurdal H: Agonist-directed trafficking explaining the difference between response pattern of naratriptan and sumatriptan in rabbit common carotid artery. Br J Pharmacol. 2002 May;136(2):171-6. [Article]
- Hoskin KL, Lambert GA, Donaldson C, Zagami AS: The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res. 2004 Feb 13;998(1):91-9. [Article]
- Boers PM, Donaldson C, Zagami AS, Lambert GA: Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B/1D) receptors in the cat: implications for migraine therapy. Cephalalgia. 2004 Feb;24(2):99-109. [Article]
- Pauwels PJ, Palmier C, Dupuis DS, Colpaert FC: Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors: intrinsic activity and modulation by G-protein activation state. Naunyn Schmiedebergs Arch Pharmacol. 1998 May;357(5):490-9. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Johnston MM, Rapoport AM: Triptans for the management of migraine. Drugs. 2010 Aug 20;70(12):1505-18. doi: 10.2165/11537990-000000000-00000. [Article]
- Dulli DA: Naratriptan: an alternative for migraine. Ann Pharmacother. 1999 Jun;33(6):704-11. [Article]
- Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. [Article]
- Massiou H: Naratriptan. Curr Med Res Opin. 2001;17 Suppl 1:s51-3. [Article]
- Lambert GA: Preclinical neuropharmacology of naratriptan. CNS Drug Rev. 2005 Autumn;11(3):289-316. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that trig...
- Gene Name
- HTR1F
- Uniprot ID
- P30939
- Uniprot Name
- 5-hydroxytryptamine receptor 1F
- Molecular Weight
- 41708.505 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Hoskin KL, Lambert GA, Donaldson C, Zagami AS: The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res. 2004 Feb 13;998(1):91-9. [Article]
- Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. [Article]
- Massiou H: Naratriptan. Curr Med Res Opin. 2001;17 Suppl 1:s51-3. [Article]
- Villalon CM, Centurion D, Valdivia LF, de Vries P, Saxena PR: Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol. 2003 Mar;1(1):71-84. [Article]
- Goadsby PJ, Classey JD: Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience. 2003;122(2):491-8. [Article]
- Villalon CM, Centurion D, Valdivia LF, De Vries P, Saxena PR: An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Serotonin binding
- Specific Function
- Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
- Gene Name
- MAOA
- Uniprot ID
- P21397
- Uniprot Name
- Amine oxidase [flavin-containing] A
- Molecular Weight
- 59681.27 Da
References
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55